SALT LAKE CITY, Nov. 1, 2023 /PRNewswire/ -- Peel Therapeutics, a clinical stage biotech company developing evolutionary based medicines, will present data on its lead clinical asset, PEEL-224, at two conferences this week. PEEL-224 is a small molecule nanoparticle engineered to improve delivery to tumors and avoid chemoresistance. PEEL-224 originates from Camptotheca acuminata, a toxin found in the Happy Tree from China. Camptothecin is a TOP1 inhibitor that interferes with DNA repair and kills damaged cells. Camptothecin has been used for thousands of years in Traditional Chinese medicine and more recently in irinotecan-based chemotherapy for solid tumors in children and adults. PEEL-224's modified TOP1 inhibitor payload and unique delivery system may offer clinical advantages to patients with solid tumors.
SALT LAKE CITY, April 13, 2023 /PRNewswire/ -- Peel Therapeutics, an evolutionary-inspired, clinical-stage biotech company, announced research conducted by the company has been published in The Journal of Thrombosis and Haemostasis. The study, NETosis Induction Reflects COVID-19 Severity and Long COVID: Insights from a Two-Center Patient Cohort Study in Israel, evaluated the ability of blood from Israeli patients with Long COVID to induce neutrophil extracellular traps (NETs) as a marker of ongoing inflammation. NETs are sticky webs of DNA released by activated immunes cells that contribute to immunothrombosis (mini-clots) and fibrosis. Peel scientists also correlated NETosis potential with acute disease severity in COVID-19. The study concluded that NET inhibitors may be a possible treatment approach for COVID-19 and recommended additional research to confirm findings. Peel Therapeutics is developing first-in-class Neutrophil Targeting Peptides (NTPs) – originating from natural NET inhibitors in newborns – to block inflammation leading to immunothrombosis and fibrosis.
Peel Therapeutics Initiates Clinical Trial of PEEL-224
SALT LAKE CITY, Aug. 24, 2020 /PRNewswire/ -- Researchers have modified a derivative of a plant toxin and linked it to a nanocarrier to create a powerful new therapeutic for childhood tumors. The new drug and its ability to eliminate chemoresistant tumors in mice is described in a new study published in Cancer Research, a journal of the American Association for Cancer Research. An exclusive license to develop the drug has been obtained by PEEL Therapeutics, Inc.